STAT2 antibody (Internal Region, pTyr690)

Catalog No. ABIN964892

Product Details anti-STAT2 Antibody

Target: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Binding Specificity: Internal Region, pTyr690

Reactivity: Human, Rat, Mouse, Cow, Dog, Horse, Macaque, Pig, Vervet Monkey, Chimpanzee

Host: Rabbit

Clonality: Polyclonal

Conjugate: This STAT2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Specificity: This affinity purified antibody is directed against human STAT2 pY690 protein.  The product was affinity purified from monospecific antiserum by immunoaffinity chromatography.  A BLAST analysis was used to suggest cross-reactivity with STAT2 pY690 protein from human, rat (73%) and mouse (76%), sources based on homology with the immunizing sequence.  Reactivity against homologues from other sources is not known.

Cross-Reactivity: Chimpanzee, Macaque, Vervet Monkey (Chlorocebus pygerythrus), Rat (Rattus), Dog (Canine), Pig (Porcine), Horse (Equine), Mouse (Murine), Sheep (Ovine)

Characteristics: This antibody is designed, produced, and validated as part of a collaboration with the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. STAT2 is a member of the STAT family of transcription factors. Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex. This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription. Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation. IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment. Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha. Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer. From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.

Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to a region near the N-terminus of human STAT2 protein.
Immunogen Type: Peptide

Isotype: IgG

Application Details

Application Notes: This affinity purified antibody has been tested for use in ELISA and western blotting.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 113 kDa in size corresponding to STAT2 pY690 protein by western blotting in the appropriate cell lysate or extract.

Comment:

Gene Name: STAT2

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.15 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Store vial at 4 °C prior to restoration. For extended storage aliquot contents and freeze at -20 °C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use. Expiration date is three (3) months from date of opening.

Expiry Date: 3 months

References for anti-STAT2 antibody (ABIN964892)

Yamauchi, Takeuchi, Chihara, Honjoh, Kato, Yoshiki, Hotta, Sada: "STAT1 is essential for the inhibition of hepatitis C virus replication by interferon-λ but not by interferon-α." in: Scientific reports, Vol. 6, pp. 38336, (2018) (PubMed).

Target Details for STAT2

Target: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Alternative Name: STAT2 (STAT2 Products)

Synonyms: wu:fj84d07 antibody, p113 antibody, stat2 antibody, 1600010G07Rik antibody, AW496480 antibody, ISGF-3 antibody, P113 antibody, STAT113 antibody, signal transducer and activator of transcription 2 antibody, AGAP000099-PA antibody, stat2 antibody, STAT2 antibody, Stat2 antibody

Background: This antibody is designed, produced, and is suitable for Cancer, Immunology and Nuclear Signaling research. STAT2 is a member of the STAT family of transcription factors.  Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex.  This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription.  Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation.  IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment.  Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha.  Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer.  From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.
Synonyms: interferon alpha induced transcriptional activator antibody, ISGF3 antibody, MGC59816 antibody, P113 antibody, signal transducer and activator of transcription 2 113kD antibody, STAT113 antibody

Gene ID: 6773, 4885615

UniProt: P52630

Pathways: JAK-STAT Signaling, Hepatitis C, CXCR4-mediated Signaling Events